Urological cancers - recognition and referral
Exam Tips
- In UK exams, haematuria age thresholds are high-yield: visible unexplained haematuria age >=45 (or persistent after UTI treatment) needs suspected bladder/renal cancer referral.
- For bladder cancer criteria, non-visible haematuria plus dysuria or raised WCC in age >=60 is a 2-week-wait trigger.
- A malignant-feeling prostate on DRE or PSA above age-specific range warrants urgent suspected prostate cancer referral.
- Non-painful testicular enlargement/change in texture is cancer until proven otherwise; arrange urgent pathway and/or direct access ultrasound.
- Persistent penile lesion after STI treatment, or penile mass/ulcer once STI excluded, should trigger suspected penile cancer referral.
- Use symptom overlap differentials actively (BPH, UTI, stones, STI) but do not let them delay referral when NICE red flags are met.
- See Figure from page 2 of the NICE CKS presentation section for site-specific symptom patterns and referral logic.
Definition
Urological cancers are malignant tumours arising from the prostate, bladder, kidney, testis, or penis, and in UK primary care they are identified mainly through symptom-pattern recognition and urgent referral thresholds. The core clinical task is to distinguish common benign urological presentations from red-flag features (especially age-related haematuria criteria, malignant-feeling prostate, and persistent testicular or penile abnormalities) that require suspected cancer pathway referral.
Pathophysiology
These cancers arise through site-specific malignant transformation: prostate adenocarcinoma usually begins in the peripheral zone and may remain asymptomatic until extracapsular or metastatic spread (classically to bone); urothelial carcinoma of the bladder develops from dysplastic urothelium, strongly linked to carcinogen exposure; renal cell carcinoma arises from renal tubular epithelium with early haematogenous potential; most testicular cancers are germ-cell tumours (seminoma/non-seminoma) with early lymphatic spread to retroperitoneal nodes; penile squamous carcinoma is associated with chronic inflammation and HPV-related dysplasia. Shared mechanisms include cumulative DNA damage, chronic inflammation, and delayed diagnosis when symptoms overlap with benign disease.
Risk Factors
- Increasing age (especially prostate, bladder, renal cancers)
- Male sex (all listed cancers; bladder/renal also occur in women)
- Smoking (strong for bladder and renal cancer)
- Family history/genetic predisposition (e. g, prostate cancer, BRCA-related risk)
- Occupational carcinogen exposure (e. g, aromatic amines for bladder cancer)
- Cryptorchidism and prior testicular cancer (testicular cancer risk)
- HPV infection, phimosis, and chronic balanitis/poor genital hygiene (penile cancer risk)
- Obesity and hypertension (renal cancer association)
Clinical Features
Symptoms
- Visible haematuria (especially age >=45 with no UTI explanation, or persisting/recurring after UTI treatment)
- Non-visible haematuria with dysuria or raised white cell count in age >=60
- Lower urinary tract symptoms: nocturia, frequency, hesitancy, urgency, retention
- Erectile dysfunction (possible prostate cancer association in assessment pathway)
- Dysuria and urinary frequency, particularly persistent/recurrent
- Loin pain or recurrent/persistent unexplained UTI (possible renal/bladder malignancy context)
- Non-painful testicular enlargement or altered shape/texture
- Persistent penile ulcer/lesion or penile mass after STI exclusion/treatment
- Unexplained weight loss, appetite loss, or cancer-associated DVT
Signs
- Hard, irregular, or nodular prostate on digital rectal examination
- Palpable flank mass (renal malignancy concern)
- Testicular asymmetry, firm intratesticular mass, or persistent texture change
- Ulcerated or indurated penile lesion, especially on glans/foreskin
- Evidence of metastatic disease (e. g, bony tenderness, pathological fracture features)
Investigations
Management
Lifestyle Modifications
- Urgent safety-netting: advise patients to re-present promptly for persistent haematuria, recurrent UTI symptoms, testicular change, or penile lesions
- Smoking cessation support (reduces future urothelial and renal cancer risk, improves perioperative outcomes)
- Discuss fertility and sperm banking early in likely testicular cancer pathways
- Optimise cardiovascular/metabolic health before definitive therapy where possible
- Clear explanation of referral urgency (2-week suspected pathway; target diagnosis/rule-out within 28 days)
Pharmacological Treatment
Antibiotics for proven/suspected UTI while assessing haematuria cause
- Nitrofurantoin modified-release 100 mg twice daily (typical lower UTI course; use only if renal function adequate)
- Trimethoprim 200 mg twice daily (alternative where suitable)
Treat documented infection, then reassess. Do not attribute persistent/recurrent haematuria to infection alone. Nitrofurantoin is generally avoided if eGFR <45 mL/min/1.73 m2 (short-course use at lower eGFR only on specialist/local advice); caution in G6PD deficiency and possible pulmonary/hepatic toxicity with prolonged use.
Analgesia for symptom control pending specialist treatment
- Paracetamol 1 g up to four times daily (max 4 g/day)
- Morphine sulfate immediate-release 5-10 mg orally every 4 hours as needed, then titrate clinically
Use WHO-style escalation and bowel regimen with opioids. Avoid NSAIDs or use cautiously in renal impairment/dehydration; monitor sedation, constipation, and respiratory depression with opioids.
Specialist systemic therapy for confirmed advanced prostate cancer
- Goserelin 3.6 mg subcutaneous implant every 28 days (or 10.8 mg every 12 weeks)
- Bicalutamide 50 mg once daily (commonly started before/with LHRH agonist to reduce tumour flare risk)
- Degarelix 240 mg loading dose then 80 mg monthly subcutaneously
Initiated in secondary care after diagnostic confirmation/staging. Key safety issues: tumour flare with LHRH agonists (consider anti-androgen cover), metabolic/cardiovascular adverse effects, QT-risk interactions, and liver toxicity monitoring with anti-androgens.
Surgical / Interventional
- Prostate: transperineal biopsy for diagnosis; definitive options include radical prostatectomy in selected localized disease
- Bladder: transurethral resection of bladder tumour (TURBT) for diagnosis and initial treatment; intravesical therapy directed by specialist risk stratification
- Renal: partial or radical nephrectomy depending on tumour stage/location
- Testicular: radical inguinal orchidectomy (diagnostic and therapeutic first step)
- Penile: excision biopsy for diagnosis; organ-preserving surgery or partial/total penectomy for invasive disease
Complications
- Metastatic spread (bone in prostate cancer; nodal and visceral spread in others)
- Pathological fractures and cancer-related pain syndromes
- Urinary obstruction, recurrent infections, and haematuria-related anaemia
- Renal impairment from obstruction or nephrectomy-related reduced renal reserve
- Venous thromboembolism
- Sexual dysfunction, infertility, and major psychosocial morbidity
Prognosis
Prognosis varies widely by tumour type and stage at diagnosis. UK figures indicate approximate 5-year survival of 49% for bladder cancer, over 65% for renal cancer, around 97% for testicular cancer, and over 80% for penile cancer in younger men; prostate cancer is often indolent but metastatic presentations have substantially worse outcomes (around half surviving 5 years).
Sources & References
✅NICE Guidelines(1)
📖Textbook References(4)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 115)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1013)[context]
- Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 718)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 276)[context]